Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vortioxetine in Bipolar II Depression
NCT05481957Phase 4Completed
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Mar 2022
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of vortioxetine in bipolar disorder (BD) (3 arms), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoint: Montgomery-Asberg Depression Rating Scale. Started Mar 2022; status: completed.
02
Drugs
vortioxetine
03
Conditions
bipolar disorder (BD)
Beyond the preview
Go deeper on NCT05481957.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05481957.